Retrospective comparison of direct in-bore magnetic resonance imaging (MRI)-guided biopsy and fusion-guided biopsy in patients with MRI lesions which are likely or highly likely to be clinically significant prostate cancer - Summary - MDSpire
Advertisement
Retrospective comparison of direct in-bore magnetic resonance imaging (MRI)-guided biopsy and fusion-guided biopsy in patients with MRI lesions which are likely or highly likely to be clinically significant prostate cancer
To compare the detection rates of clinically significant prostate cancer (csPCa) between direct in-bore MRI-guided biopsy (MRGB) and MRI-TRUS fusion-guided biopsy (FGB), highlighting the clinical significance of these techniques.
Key Findings:
FGB was performed on 51 patients targeting 58 lesions, while MRGB included 227 patients.
Both biopsy techniques aimed at lesions classified as PI-RADS 4 or 5 and ≥8 mm in size.
The study found comparable detection rates of csPCa between FGB and MRGB, with statistical analysis confirming this comparability.
Interpretation:
The findings suggest that FGB may be as effective as MRGB in detecting clinically significant prostate cancer, providing a potentially more accessible and cost-effective option for patients.
Limitations:
The study was retrospective and conducted at a single institution, which may introduce bias.
The experience level of the radiologist performing FGB was limited compared to that of MRGB.
Conclusion:
FGB could serve as a viable alternative to MRGB for detecting clinically significant prostate cancer, especially given its greater accessibility and lower costs, but further studies are needed to validate these findings.
by Wulphert Venderink, Marloes van der Leest, Annemarijke van Luijtelaar, Wendy J. M. van de Ven, Jurgen J. Fütterer, J. P. Michiel Sedelaar, Henkjan J. Huisman
